Bohuslav Melichar
#150,151
Most Influential Person Now
Researcher
Bohuslav Melichar's AcademicInfluence.com Rankings
Bohuslav Melicharcomputer-science Degrees
Computer Science
#7837
World Rank
#8245
Historical Rank
Computational Linguistics
#1651
World Rank
#1668
Historical Rank
Machine Learning
#3042
World Rank
#3080
Historical Rank
Artificial Intelligence
#3336
World Rank
#3385
Historical Rank
Download Badge
Computer Science
Bohuslav Melichar's Degrees
- PhD Computer Science Charles University
- Masters Computer Science Charles University
- Bachelors Computer Science Charles University
Similar Degrees You Can Earn
Why Is Bohuslav Melichar Influential?
(Suggest an Edit or Addition)Bohuslav Melichar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial (2007) (2234)
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1808)
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial (2014) (1725)
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019) (1244)
- Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. (2010) (784)
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. (2015) (688)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019) (611)
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. (2021) (533)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2013) (391)
- Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. (2013) (334)
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. (2019) (323)
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. (2012) (299)
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (2020) (276)
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. (2017) (261)
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. (2014) (233)
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. (2013) (230)
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. (2021) (222)
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. (2016) (212)
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study. (2015) (193)
- Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. (2008) (189)
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. (2015) (122)
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma. (2021) (99)
- Tumor-Infiltrating Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma (2008) (98)
- Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study. (2015) (97)
- Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. (2006) (96)
- Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. (2000) (96)
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. (2012) (93)
- CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (2017) (90)
- From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer (2018) (89)
- Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC). (2009) (89)
- Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA‐4 on malignant ascites CD3+ tumour‐infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis (2000) (88)
- A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon- α2a as first-line therapy in metastatic renal cell carcinoma (2007) (86)
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. (2013) (84)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. (2019) (82)
- Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2 (2013) (75)
- Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. (2015) (72)
- Immunology of the peritoneal cavity: Relevance for host-tumor relation (2001) (72)
- Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. (2003) (72)
- Eye complications of cetuximab therapy. (2007) (70)
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. (2015) (70)
- Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry. (2012) (69)
- Intestinal Permeability in the Assessment of Intestinal Toxicity of Cytotoxic Agents (2005) (66)
- FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. (2014) (66)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity. (2016) (66)
- Biochemical profile and survival in nonagenarians. (2001) (66)
- Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients (1997) (65)
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. (2012) (64)
- Determination of lipidomic differences between human breast cancer and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis (2014) (64)
- CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. (2001) (63)
- Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. (1998) (62)
- Increased urinary neopterin in acute myocardial infarction. (1994) (62)
- HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up. (2016) (61)
- Intestinal permeability in patients with chemotherapy-induced stomatitis (2001) (60)
- Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. (1996) (59)
- Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. (2015) (58)
- The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer (2013) (58)
- Predictive and prognostic significance of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant systemic therapy. (2014) (57)
- Urinary neopterin in patients with advanced colorectal carcinoma. (2006) (57)
- Optimization and validation of a high performance liquid chromatography method for the simultaneous determination of vitamins A and E in human serum using monolithic column and diode-array detection. (2006) (57)
- Laboratory medicine and medical oncology: the tale of two Cinderellas (2012) (57)
- FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma (2016) (56)
- Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis (2016) (56)
- Abstract S2-02: The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer – Part I results (2015) (56)
- Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. (2016) (54)
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. (2013) (54)
- Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial (2019) (53)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021) (52)
- Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab (2016) (52)
- Lipidomic differentiation between human kidney tumors and surrounding normal tissues using HILIC-HPLC/ESI-MS and multivariate data analysis. (2015) (51)
- Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial (2011) (51)
- MAESTRO: A randomized, double-blind phase III study of evofosfamide (Evo) in combination with gemcitabine (Gem) in previously untreated patients (pts) with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). (2016) (49)
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer (2015) (49)
- Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial (2019) (48)
- Growth inhibitory effects of aromatic fatty acids on ovarian tumor cell lines. (1998) (47)
- Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-γ expression (2004) (47)
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. (2020) (46)
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis (2014) (46)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer (2016) (44)
- Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer (2017) (43)
- Tailored immunotherapy approach with nivolumab in advanced renal cell carcinoma (TITAN-RCC) (2019) (43)
- Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer (2020) (42)
- Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. (2004) (42)
- G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab (2016) (40)
- Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. (2016) (39)
- Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. (2012) (39)
- Neopterin as a biomarker of immune response in cancer patients. (2017) (38)
- THE PERIPHERAL BLOOD LEUKOCYTE PHENOTYPE IN PATIENTS WITH BREAST CANCER: EFFECT OF DOXORUBICIN/PACLITAXEL COMBINATION CHEMOTHERAPY (2001) (38)
- Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. (2016) (37)
- Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. (2014) (36)
- Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). (2017) (36)
- Intima-media thickness, myocardial perfusion and laboratory risk factors of atherosclerosis in patients with breast cancer treated with anthracycline-based chemotherapy (2011) (34)
- Evofosfamide (TH-302) in combination with gemcitabine in previously untreated patients with metastatic or locally advanced unresectable pancreatic ductal adenocarcinoma: Primary analysis of the randomized, double-blind phase III MAESTRO study. (2016) (32)
- Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro. (1997) (32)
- Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. (2009) (31)
- Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer (2017) (31)
- Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature (2017) (31)
- Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma (2003) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Determination of neopterin, kynurenine, tryptophan and creatinine in human serum by high throuput HPLC. (2011) (31)
- Metastases of esophageal carcinoma to skeletal muscle: single center experience. (2012) (30)
- A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. (2013) (29)
- A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer (2017) (28)
- MALDI Orbitrap Mass Spectrometry Profiling of Dysregulated Sulfoglycosphingolipids in Renal Cell Carcinoma Tissues (2017) (28)
- Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database (2012) (28)
- RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer (2017) (28)
- Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer (2018) (28)
- Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. (2007) (27)
- Successful management of infusion reaction accompanying the start of cetuximab therapy (2007) (26)
- Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. (2015) (26)
- Synchronous Second Primary Neoplasms Detected by Initial Staging F-18 FDG PET/CT Examination in Patients With Non-Hodgkin Lymphoma (2011) (26)
- The significance of altered gastrointestinal permeability in cancer patients (2011) (26)
- The association between specific nutritional antioxidants and manifestation of colorectal cancer. (2000) (25)
- Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses (2014) (25)
- Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. (2020) (25)
- Lipidomic profiling of human serum enables detection of pancreatic cancer (2021) (25)
- Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. (2021) (25)
- HILIC/ESI-MS determination of gangliosides and other polar lipid classes in renal cell carcinoma and surrounding normal tissues (2018) (24)
- Role of solute carrier transporters in pancreatic cancer: a review. (2014) (24)
- Urinary Neopterin in Patients with Ovarian Cancer (2006) (24)
- Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer (2016) (24)
- Citrulline as a biomarker of gastrointestinal toxicity in patients with rectal carcinoma treated with chemoradiation (2016) (24)
- Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adeno (2016) (24)
- Oral ridaforolimus plus trastuzumab for patients with HER2+ trastuzumab-refractory metastatic breast cancer. (2015) (23)
- Reversed phase UHPLC/ESI-MS determination of oxylipins in human plasma: a case study of female breast cancer (2019) (23)
- Systemic Immune Activation, Anemia and Thrombocytosis in Breast Cancer Patients Treated by Doxorubicin and Paclitaxel (2006) (23)
- Intestinal Permeability and Vitamin A Absorption in Patients With Chemotherapy-Induced Diarrhea (2008) (23)
- Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study. (2012) (23)
- Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma. (2015) (22)
- 3,5-disubstituted pyranone analogues of highly antifungally active furanones: conversion of biological effect from antifungal to cytostatic. (2010) (22)
- Zolbetuximab combined with EOX as first-line therapy in advanced CLDN18.2+ gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma: Updated results from the FAST trial. (2019) (22)
- Intraluminal high dose rate brachytherapy in the treatment of bile duct and gallbladder carcinomas. (2002) (22)
- Lipidomic characterization of exosomes isolated from human plasma using various mass spectrometry techniques. (2020) (21)
- Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial. (2009) (21)
- Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry (2017) (21)
- A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. (2015) (20)
- Correlation of lipidomic composition of cell lines and tissues of breast cancer patients using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry and multivariate data analysis. (2017) (20)
- Increased Urinary Nitrate Excretion in Inflammatory Bowel Disease (1994) (20)
- Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. (2015) (20)
- rIFN-γ-mediated growth suppression of platinum-sensitive and -resistant ovarian tumor cell lines not dependent upon arginase inhibition (2003) (20)
- Systemic Inflammatory Response After Open, Laparoscopic and Robotic Surgery in Endometrial Cancer Patients. (2016) (20)
- Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum (2007) (19)
- Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy. (2008) (19)
- Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC). (2015) (19)
- Fluorescence analysis of antioxidant vitamins and neopterin in nonagenarians (1999) (19)
- Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view (2015) (18)
- Intraarterial chemotherapy of malignant melanoma metastatic to the liver. (2001) (18)
- CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer. (2017) (18)
- Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR. (2015) (18)
- Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis (2014) (17)
- Anorectal Carcinoma After Infliximab Therapy in Crohn’s Disease: Report of a Case (2006) (17)
- ABC Transporters and Their Role in the Neoadjuvant Treatment of Esophageal Cancer (2018) (17)
- Growth-inhibitory effect of a novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, on ovarian carcinoma cell lines not dependent on peroxisome proliferator-activated receptor-gamma expression. (2004) (17)
- Targeted therapy for HER-2: personalized medicine for her, too (2012) (17)
- Prognostic significance of increased urinary neopterin concentrations in patients with breast carcinoma. (2011) (17)
- Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor (2017) (17)
- Patupilone in chemotherapy-pretreated patients with advanced colorectal cancer (CRC) receiving nutritional support and intensive diarrhea management: A phase I multicenter trial. (2006) (17)
- Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry (2014) (17)
- Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics. (2011) (17)
- HPLC method for simultaneous determination of retinoids and tocopherols in human serum for monitoring of anticancer therapy. (2009) (16)
- Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial (2011) (16)
- Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects. (2006) (16)
- Regional chemotherapy in biliary tract cancers--a single institution experience. (2002) (16)
- Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. (2009) (16)
- Spontaneous regression of renal cell carcinoma lung metastases in a patient with psoriasis (2009) (16)
- Effect of irinotecan on the phenotype of peripheral blood leukocyte populations in patients with metastatic colorectal cancer. (2002) (16)
- Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial. (2021) (15)
- Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice (2016) (15)
- Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). (2016) (15)
- Non-invasive determination of uric acid in human saliva in the diagnosis of serious disorders (2020) (15)
- ROMA or death: advances in epithelial ovarian cancer diagnosis (2011) (14)
- Determination of one year stability of lipid plasma profile and comparison of blood collection tubes using UHPSFC/MS and HILIC-UHPLC/MS. (2020) (14)
- Urinary Neopterin and Microalbuminuria in Patients Treated by Low-density Lipoprotein Apheresis (2005) (14)
- Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy. (2005) (14)
- Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. (2009) (14)
- LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) (2014) (14)
- Immunotherapy in mucosal melanoma: a case report and review of the literature (2018) (14)
- Palbociclib plus cetuximab versus placebo plus cetuximab in platinum-resistant, cetuximab-naive, HPV-unrelated head and neck cancer: A double-blind randomized phase II trial (PALATINUS). (2019) (14)
- Expression of Bcl-2 in Breast Cancer: Correlation with Clinicopathological Characteristics and Survival. (2008) (13)
- Risk factors of atherosclerosis during systemic therapy targeting vascular endothelial growth factor (2015) (13)
- Potential Predictive Role of MicroRNAs in the Neoadjuvant Treatment of Esophageal Cancer. (2017) (13)
- Fast and sensitive HPLC method for the determination of neopterin, kynurenine and tryptophan in amniotic fluid, malignant effusions and wound exudates. (2015) (13)
- Laboratory medicine: an essential partner in the care of cancer patients (2011) (13)
- Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. (2014) (13)
- Serum alpha-tocopherol, retinol and neopterin during paclitaxel/carboplatin chemotherapy. (2007) (13)
- Hepatic arterial infusion in colorectal carcinoma: is anatomical targeting still relevant in an era of molecularly targeted therapy? (2012) (13)
- Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? (2013) (13)
- Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study. (2013) (13)
- Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma (2012) (12)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. (2019) (12)
- Hypomagnesaemia in patients with metastatic colorectal carcinoma treated with cetuximab. (2012) (12)
- Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience. (2010) (12)
- Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial. (2013) (12)
- Intestinal permeability, vitamin A absorption, alpha-tocopherol, and neopterin in patients with rectal carcinoma treated with chemoradiation (2010) (12)
- Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer (2021) (12)
- The Phenotype of Ascitic Fluid Lymphocytes in Patients with Ovarian Carcinoma and Other Primaries (2001) (12)
- Serial Urinary Neopterin Measurements Reflect the Disease Course in Patients with Epithelial Ovarian Carcinoma Treated with Paclitaxel/Platinum Chemotherapy (2007) (12)
- Hepatic arterial administration of activated leukocytes in patients with liver metastases. (2002) (12)
- Urinary Neopterin in Patients with Advanced Colorectal Carcinoma (2006) (12)
- Serum retinol, alpha-tocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab. (2010) (11)
- Intestinal permeability in patients with metastatic colon cancer treated with patupilone (2014) (11)
- Hepatic Arterial Infusion Chemotherapy in Gastric Cancer: A Report of Four Cases and Analysis of the Literature (2004) (11)
- Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome (2017) (11)
- Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: a registry-based analysis. (2014) (11)
- BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC). (2011) (11)
- Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. (2014) (11)
- Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results. (2013) (11)
- Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms. (2021) (11)
- Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. (2015) (11)
- Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study (2003) (11)
- Biomarkers in the treatment of cancer: opportunities and pitfalls (2013) (11)
- Chromatographic method for the determination of inflammatory biomarkers and uric acid in human saliva. (2021) (11)
- Survival of patients with colorectal cancer liver metastases treated by regional chemotherapy. (2006) (11)
- Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients. (2018) (10)
- Association between renal tubular cell dysfunction and increased urinary zinc excretion in cancer patients. (1995) (10)
- Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. (2021) (10)
- Carotid intima-media thickness and laboratory parameters of atherosclerosis risk in patients with breast cancer. (2012) (10)
- Lenvatinib for the treatment of kidney cancer (2018) (10)
- Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinoma. (2016) (10)
- Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study (2015) (10)
- Transduodenal intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region. (2002) (10)
- Intraperitoneal Fluid Neopterin, Nitrate, and Tryptophan After Regional Administration of Interleukin-12 (2003) (10)
- Polyunsaturated fatty acids, phytosterols and cholesterol metabolism in the Mediterranean diet. (2006) (10)
- Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry (2017) (10)
- Urinary Neopterin in Patients with upper Gastrointestinal, Biliary and Pancreatic Carcinomas (2006) (9)
- Phenotype of peripheral blood leukocytes and survival of patients with metastatic colorectal cancer. (2005) (9)
- Hepatic Arterial Infusion Chemotherapy in Sarcoma Liver Metastases: A Report of 6 Cases (2005) (9)
- Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases (2012) (9)
- Epidermal Growth Factor Receptor as a Predictor of Tumor Response to Preoperative Chemoradiation in Locally Advanced Gastric Carcinoma (2008) (9)
- Abstract CT111: Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial (2018) (9)
- Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. (2021) (9)
- Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. (2021) (9)
- Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients with Rectal Carcinoma Treated with Chemoradiation. (2016) (9)
- Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis (2012) (9)
- Rethinking internal quality control: the time is now (2022) (9)
- Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice (2012) (9)
- Hepatocellular carcinoma presenting with bone metastasis. (2002) (9)
- Plasma lipidomic profiles of kidney, breast and prostate cancer patients differ from healthy controls (2021) (9)
- Breast cancer, locally advanced and metastatic (2012) (9)
- Urinary Neopterin in Patients with Liver Tumors (2006) (9)
- Recent advances in the determination of tocopherols in biological fluids: from sample pretreatment and liquid chromatography to clinical studies (2016) (9)
- Two-dimensional electrophoretic study of normal colon mucosa and colorectal cancer. (1994) (8)
- Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma. (2009) (8)
- Urinary Neopterin in Patients with Metastatic Colon Cancer Treated with Patupilone (2011) (8)
- Omission of adjuvant radiation therapy in elderly patients with low risk breast cancer undergoing breast-conserving surgery--two center experience. (2013) (8)
- Predictive Parameters for Internal Mammary Node Drainage in Patients with Early Breast Cancer (2014) (8)
- Role of subcutaneous formulation of trastuzumab in the treatment of patients with HER2-positive breast cancer. (2014) (8)
- Prognostic significance of serum retinol, serum alpha-tocopherol, and urinary neopterin in patients with head and neck carcinoma treated with external beam radiation. (2012) (8)
- Risk factors of atherosclerosis in patients with history of breast cancer (2013) (8)
- PSA, PCA3 and the phi losophy of prostate cancer management (2013) (8)
- Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. (2022) (8)
- Correlations of neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios with biomarkers of atherosclerosis risk and inflammatory response in patients with a history of breast cancer (2015) (8)
- Phase I dose optimization trial of patupilone in previously treated patients (pts) with advanced colon cancer (ACC) (2005) (8)
- Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors. (2011) (8)
- Trends in peritoneal surface malignancies: evidence from a Czech nationwide population-based study (2019) (8)
- Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis (2018) (8)
- Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin. (2005) (8)
- Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry (2015) (7)
- Regional administration of irinotecan in combination with 5-fluorouracil and leucovorin in patients with colorectal cancer liver metastases--a pilot experience. (2001) (7)
- Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC). (2015) (7)
- Sarcopenia in Metastatic Renal Cell Carcinoma Patients Treated with Cabozantinib (2020) (7)
- The Theranos phenomenon, scientific transparency and freedom of speech (2016) (7)
- Scientific publishing in the “predatory” era (2017) (7)
- Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma --review of the literature I. (2006) (7)
- Pegylated Liposomal Doxorubicin in Combination With Hyperthermia in the Treatment of a Case of Advanced Hepatocellular Carcinoma (2002) (7)
- Increased urinary zinc excretion in cancer patients is linked to immune activation and renal tubular cell dysfunction (1995) (7)
- Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study (2021) (7)
- Tumor biomarkers: PSA and beyond (2012) (7)
- Folate receptor: a potential target in ovarian cancer (2015) (7)
- Intra-laboratory comparison of four analytical platforms for lipidomic quantitation using hydrophilic interaction liquid chromatography or supercritical fluid chromatography coupled to quadrupole - time-of-flight mass spectrometry. (2021) (7)
- Systemic Immune Activation and Peripheral Blood Lymphocytes during Primary Chemotherapy with the Combination of Doxorubicin and Paclitaxel in Patients with Breast Carcinoma (2007) (7)
- Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry (2020) (7)
- Significance of the resection margin and risk factors for close or positive resection margin in patients undergoing breast-conserving surgery. (2012) (7)
- A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma. (2020) (7)
- 4518 POSTER First-line bevacizumab improves progression-free survival with lower doses of interferon-a2a in the treatment of patients with metastatic renal cell carcinoma (AVOREN) (2007) (7)
- Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy. (2009) (7)
- Systemic immune response and peripheral blood cell count in patients with a history of breast cancer (2013) (7)
- Urinary neopterin concentrations during combination therapy with cetuximab in previously treated patients with metastatic colorectal carcinoma. (2014) (7)
- Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. (2015) (7)
- Hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. (2012) (7)
- Urinary Neopterin Excretion in Colorectal Cancer (1994) (7)
- Cerebrospinal Fluid Neopterin in Patients with Tumors and other Disorders (2008) (7)
- Safety of mTOR inhibitors in breast cancer (2016) (6)
- Association of the combined parameters including the frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression with the outcome in intestinal cancer. (2017) (6)
- Cancer incidence and mortality in the Czech Republic. (2014) (6)
- Stereotactic radiotherapy in the treatment of local recurrences of esophageal cancer. (2017) (6)
- Effect of comorbidity on urinary neopterin in patients with breast carcinoma. (2010) (6)
- [Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies]. (2018) (6)
- Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice (2020) (6)
- Significance of resection margin as a risk factor for local control of early stage breast cancer. (2013) (6)
- Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis (2018) (6)
- Cancer diagnosis: from dogs to DNA or from DNA to dogs? (2012) (6)
- Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial (2016) (6)
- Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL). (2015) (6)
- Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib (2010) (6)
- Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients (2020) (6)
- Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients (2020) (6)
- Outcomes of Patients With Long‐Term Treatment Response to Vascular Endothelial Growth Factor‐Targeted Therapy for Metastatic Renal Cell Cancer (2017) (6)
- Urinary Neopterin in Patients with Diabetes Mellitus and Foot Ulcers (2007) (6)
- The changes of tumour vascular endothelial growth factor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma (2017) (6)
- Urinary neopterin concentration and toxicity of radiotherapy in patients with head and neck carcinoma during external beam radiation. (2013) (6)
- 4008 POSTER Bevacizumab/interferon-alpha2a provides a progression-free survival benefit in all prespecified patient subgroups as first-line treatment of metastatic renal cell carcinoma (AVOREN) (2007) (6)
- Prognostic Influence of Internal Mammary Node Drainage in Patients with Early-stage Breast Cancer. (2016) (6)
- Treatment of brain metastases. (2016) (6)
- How Can Second-Line Therapy for Metastatic Renal Cell Carcinoma Help to Define an Overall Management Strategy? (2008) (6)
- Lipidomic profiling of human serum enables detection of pancreatic cancer (2022) (6)
- Metastatic colorectal carcinoma and kidney tumors: a report of four cases. (2010) (6)
- Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. (2019) (6)
- 7131 POSTER Optimizing the Sequencial Treatment of Metastatic Renal Cell Carcinoma (MRCC) – a Retrospective, Multicenter, Analysis of 40 Patients Treated With Either Sorafenib, an mTOR Inhibitor (mTORI) and Sunitinib, or Sunitinib, an mTORI and Sorafenib (2011) (6)
- Severe tyrosine-kinase inhibitor induced liver injury in metastatic renal cell carcinoma patients: two case reports assessed for causality using the updated RUCAM and review of the literature (2022) (5)
- Gastroduodenal, intestinal and colonic permeability during anticancer therapy. (2011) (5)
- Gastrointestinal Permeability - a Parameter of Possible Prognostic Importance in Metastatic Colorectal Carcinoma (2008) (5)
- Intraluminal high dose rate brachytherapy of tumorous esophageal stenoses. (2006) (5)
- CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer. (2017) (5)
- Management of severe infusion reactions after cetuximab (2008) (5)
- Fulminant course of metastatic liposarcoma after delivery--case report. (2007) (5)
- Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial (2022) (5)
- Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study. (2020) (5)
- Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. (2019) (5)
- Metastatic Clear Cell Renal Carcinoma Without Evidence of a Primary Renal Tumour Mimicking Advanced Stage of Malignant Lung Tumour. (2019) (5)
- Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma. (2014) (5)
- Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery (2018) (5)
- Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor. (2006) (5)
- Altered Plasma, Urine, and Tissue Profiles of Sulfatides and Sphingomyelins in Patients with Renal Cell Carcinoma (2022) (5)
- Expression of Claudin 18.2 and HER2 in gastric, gastroesophageal junction, and esophageal cancers: Results from the FAST study. (2017) (5)
- Clinical Chemistry and Laboratory Medicine: progress and new challenges for our 50-year-old journal (2012) (5)
- Meningeal carcinomatosis as a late complication of brain metastases of epithelial ovarian carcinoma. (2008) (5)
- Increased gastric juice nitrate is associated with biliary reflux and Helicobacter pylori infection. (1995) (5)
- Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents (2017) (5)
- PrefHer: finally addressing the preferences of her, too. (2013) (5)
- [Prognostic markers in ovarian carcinoma--retrospective study]. (2005) (4)
- Correlation of Peripheral Blood CD14+CD16+ Monocytes, Urinary Neopterin and the Risk Factors of Atherosclerosis in Patients with Breast Carcinoma (2011) (4)
- Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma. (2012) (4)
- Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer (2016) (4)
- Determination of urinary retinol and creatinine as an early sensitive marker of renal dysfunction. (2019) (4)
- Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial (2012) (4)
- Hepatic arterial infusion for biliary tract carcinoma: single-center experience. (2013) (4)
- Preoperative neoadjuvant chemoradiation for locally advanced gastric adenocarcinoma (2009) (4)
- Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy. (2014) (4)
- High Lapatinib Plasma Levels in Breast Cancer Patients: Risk or Benefit? (2012) (4)
- Quo vadis, biomarkers? (2014) (4)
- Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer (2020) (4)
- Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial. (2018) (4)
- Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. (2019) (4)
- ELEVATION DE LA NEOPTERINE APRES TRAITEMENT PAR LE FACTEUR STIMULANT DES COLONIES GRANULO-MACROPHAGIQUES (GM-CSF) (1994) (4)
- Abstract LB-67: REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p (2013) (4)
- Cost analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and the risk factors for their increased cost in a public insurance health care system - Single centre study. (2020) (4)
- Precision medicine in medical oncology: hope, disappointment and reality (2020) (4)
- An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 2 study of palbociclib (an oral CDK4/6 inhibitor) plus cetuximab in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). (2016) (4)
- Negative prognostic significance of primary cilia, CD8+ tumor infiltrating lymphocytes and PD1+ cells expression in clear cell renal cancer. (2019) (4)
- Increased urinary zinc and copper excretion in colorectal cancer. (1994) (4)
- Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. (2014) (4)
- 718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment (2020) (4)
- Prevalence of perfusion defects detected by stress 99mtechnetium sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with breast cancer. (2014) (4)
- Human epididymis protein 4: the start of a post-ROMAn era? (2012) (4)
- 7126 What is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferonalpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? – Experience from AVOREN (2009) (4)
- A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer. (2013) (4)
- Prognostic Significance of Serum Neopterin in Patients with Esophageal Carcinoma (2012) (4)
- Salivary neopterin concentrations in patients with cancer of the oral cavity (2016) (4)
- Radiotherapy management of brain metastases using conventional linear accelerator. (2016) (4)
- Pathological complete response after primary chemotherapy in a mother and daughter with hereditary breast carcinoma: two case reports. (2008) (4)
- Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma. (2020) (3)
- 7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival (2009) (3)
- Survival after oxaliplatin therapy of irinotecan-pretreated advanced colorectal cancer patients. (2005) (3)
- Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. (2019) (3)
- O-0008REGARD PHASE 3, RANDOMIZED TRIAL OF RAMUCIRUMAB IN PATIENTS WITH METASTATIC GASTRIC OR GEJ ADENOCARCINOMA FOLLOWING PROGRESSION ON FIRST-LINE CHEMOTHERAPY (2013) (3)
- [Increase of neopterin after treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF)]. (1994) (3)
- Targeted axillary dissection with preoperative tattooing of biopsied positive axillary lymph nodes in breast cancer. (2020) (3)
- Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Mullerian-Hormone-Receptor II (AMHRII), acting through Tumor-Associated Macrophage engagement in advanced/metastatic colorectal cancers. (2019) (3)
- Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting (2019) (3)
- Association of triple positivity with prognostic parameters and overall survival in a population-based study of 6,122 HER2-positive breast cancer patients: analysis of real-world clinical practice based on a research database. (2020) (3)
- Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study (2022) (3)
- Respiratory complications following mini-invasive laparoscopic and thoracoscopic esophagectomy for esophageal cancer. Experience in 215 patients (2018) (3)
- Fluorimetric determination of the levels of urinary neopterin and serum thiobarbituric acid reactive substances in the nonagenarians. (2003) (3)
- P201 Subcutaneous versus intravenous trastuzumab in early breast cancer: 2-year follow-up of HannaH (2015) (3)
- Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma. (2015) (3)
- Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations (2019) (3)
- Gastric juice neopterin in Helicobacter pylori infection. (1995) (3)
- A Phase II Multicenter Randomized Open-Label Study of Oral Steroid Sulphatase (STS) Inhibitor Irosustat (BN83495) Versus Megestrol Acetate (MA) in Women with Advanced/Recurrent Endometrial Cancer (EC) (2012) (3)
- Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters. (2019) (3)
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fl uorouracil or FOLFIRI in relation to microsatellite status : results of the PETACC-3 trial † (2014) (3)
- Brain metastases of parathyroid carcinoma: Review of the literature and a case report. (2015) (3)
- Abstract PD3-11: Efficacy and safety of subcutaneous or intravenous trastuzumab in patients with HER2-positive early breast cancer after 5 years' treatment-free follow-up: Final analysis from the phase III, open-label, randomized HannaH study (2018) (3)
- The highs and lows of tumor biomarkers: lost illusions (2015) (3)
- Urinary Neopterin, Serum Retinol, α-tocopherol and Homocysteine in Breast Cancer Patients During Treatment with Bevacizumab and Chemotherapy (2010) (3)
- Simulations of centriole of polarized centrosome as a monopole antenna in immune and viral synapses. (2018) (3)
- Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (2020) (3)
- Association of urinary neopterin, neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios with long-term survival of patients with breast cancer (2016) (3)
- Radiation-associated angiosarcoma of the breast: An international multicenter analysis. (2022) (3)
- Regional chemotherapy in patients with breast carcinoma liver metastases. (2006) (2)
- Intestinal permeability and toxicity of second-line therapeutic agents in ovarian cancer. (2008) (2)
- BCL2 is a predictive marker of adjuvant CMF regimen in triple-negative breast cancer patients (2011) (2)
- Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial. (2018) (2)
- 7121 Bevacizumab (BEV) and interferon (IFN) therapy does not increase risk of cardiac events in metastatic renal cell carcinoma (mRCC) (2009) (2)
- 518PSequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis (2017) (2)
- Pathological Complete Response to Trastuzumab Subcutaneous Fixed-Dose Formulation in the Hannah Study: Subgroup Analysis of Patient Demographics and Tumor Characteristics and Influence of Body Weight (BW) and Serum Trough Concentration (Ctrough) of Trastuzumab (2012) (2)
- Treatment sequences in metastatic renal cell carcinoma: Efficacy results from the Czech registry (RENIS). (2018) (2)
- 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2015) (2)
- Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer. (2019) (2)
- Increased Immunoglobulin E and Interferon-γ in Patients with Malignant Lymphoma (1995) (2)
- Intestinal permeability in colorectal cancer patients treated by raltitrexed or irinotecan. (2003) (2)
- Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study. (2020) (2)
- Repeated chemosensitivity testing in patients with epithelial ovarian carcinoma. (2010) (2)
- Renal cell carcinoma metastatic to the pancreas: a single center experience. (2009) (2)
- A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma (2022) (2)
- The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature (2022) (2)
- Intestinal permeability, vitamin A absorption and serum alpha-tocopherol in gastrointestinal stromal tumor patients treated with imatinib. (2010) (2)
- Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study (2022) (2)
- 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study (2021) (2)
- Comparison of performance of composite biomarkers of inflammatory response in determining the prognosis of breast cancer patients (2017) (2)
- Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma (2021) (2)
- Urinary zinc and copper excretion in cancer patients (1994) (2)
- Neoadjuvant combination therapy with trastuzumab in a breast cancer patient with synchronous rectal carcinoma: a case report and biomarker study (2017) (2)
- A double-blind, randomized, placebo-controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylase inhibitor (HDACi) entinostat in metastatic breast cancer (MBC). (2010) (2)
- CARD: Randomized, open-label study of cabazitaxel (CBZ) vs abiraterone (ABI) or enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) (2019) (2)
- Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy. (2013) (2)
- 1449MO Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study (2022) (2)
- Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors (2021) (2)
- Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis (2015) (2)
- Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol. (2010) (2)
- Metastatic Colorectal Carcinoma and Kidney Tumors: A Report of Four Cases (2010) (2)
- Population pharmacokinetics and exposure-safety relationship of nanoliposomal irinotecan (MM-398, nal-IRI) in patients with solid tumors. (2015) (2)
- [Good's syndrome (thymoma associated hypogammalobulinaemia) - 2 case reports]. (2012) (2)
- Abstract P2-09-30: Impact ofPIK3CA,PTEN and RPS6 Status on Lapatinib Treatment Outcome in Advanced-Stage Breast Cancer Patients (2010) (2)
- Biomarkers, inflammation and cancer: where to go? (2016) (2)
- HPV Status and Mutation Analysis Using Multiparallel Sequencing in Distal Oesophageal and Gastro-oesophageal Junction Adenocarcinomas. (2018) (1)
- Biomarkers in the management of lung cancer: changing the practice of thoracic oncology (2022) (1)
- [Combined Regimens in Immunotherapy]. (2019) (1)
- Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer? (2022) (1)
- 507PDPOSEIDON PHASE I/II TRIAL: ABITUZUMAB COMBINED WITH CETUXIMAB PLUS IRINOTECAN AS SECOND-LINE TREATMENT FOR PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER. (2014) (1)
- Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). (2017) (1)
- Urinary Neopterin in Patients Treated with Gefitinib (2007) (1)
- Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab (2017) (1)
- 629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study (2020) (1)
- Abstract PD5-5: Phase 2 study of single agent MLN8237 (alisertib), an investigational aurora A kinase (AAK) inhibitor, in patients (pts) with relapsed/refractory breast cancer (BrC) (2013) (1)
- [Campylobacter pylori, its detection and association with common pathologic conditions of the gastro-duodenum]. (1990) (1)
- Pharmacogenomics: from cell to clinic (Part 1). (2014) (1)
- 55O_PRPhase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival by body weight and anti-drug antibody status (2015) (1)
- [Triple malignancy in a patient with conjunctival melanoma]. (2008) (1)
- Current status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies. (2018) (1)
- 2615 Efficacy and tolerability of axitinib in metastatic renal cell carcinoma (mRCC): Comparison of Czech clinical registry and AXIS trial data (2015) (1)
- Urinary neopterin concentrations during radiotherapy for gynecological cancer (2014) (1)
- CARD: Overall survival (OS) analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel versus abiraterone or enzalutamide. (2020) (1)
- Prognostic significance of ATP-binding cassette (ABC) and solute carrier (SLC) transporters in pancreatic ductal adenocarcinoma (PDAC). (2013) (1)
- 38th International Winter-Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics Innsbruck, February 26th – March 1st, 2019 (2019) (1)
- Conference scene: pharmacogenomics: from cell to clinic (part 2). (2014) (1)
- Increased immunoglobulin E and interferon-gamma in patients with malignant lymphoma. (1995) (1)
- Abstract CT154: Isatuximab (Isa) plus atezolizumab (Atezo) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label multicenter study (2021) (1)
- Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report (2020) (1)
- Chromatographic methods development for clinical practice: requirements and limitations (2020) (1)
- Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies (2004) (1)
- 1945 Phase III HannaH study of subcutaneous or intravenous trastuzumab for HER2-positive early breast cancer: Exploratory subgroup analyses of pathological complete response and 3-year event-free survival according to body weight and anti-drug antibody status (2015) (1)
- Rectal carcinoma after radiotherapy for cervical carcinoma in patients with a family history of colorectal carcinoma: report of two cases. (2007) (1)
- Palliative hepatic arterial infusion in renal cell carcinoma spreading to the liver: a retrospective analysis. (2010) (1)
- Substance P increases Helicobacter pylori-induced leukocyte chemiluminescence (1994) (1)
- Palliative Hepatic Arterial Infusion in Renal Cell Carcinoma Spreading to the Liver: A Retrospective Analysis (2010) (1)
- A phase I, dose-finding study of orally administered S-1 in combination with epirubicin and oxaliplatin (EOS) in patients (pts) with advanced or metastatic gastrointestinal cancer (AGIC) and chemonaïve advanced esophagogastric cancer (AEGC). (2015) (1)
- Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors (2021) (1)
- Growth factor receptor 1 and 2 (HER1 and HER2) gene and protein assessment and evaluation of lapatinib plasma concentrations (PCs) in breast cancer patients (2010) (1)
- Abstract 4152: The detection of circulating tumor cells is a negative prognostic factor in pancreatic cancer (2010) (1)
- Serum Neopterin, Retinol and Alpha-tocopherol in Patients with the Carcinoma of the Esophagus (2009) (1)
- Serum Neopterin and Angiotensin-converting Enzyme In Cancer Patients (1994) (1)
- Bevacizumab (BEV) + Low-Dose Interferon-α2A (IFN) for First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC): Final Safety and Efficacy Data from the Prospective Bevlin Study (2012) (1)
- Concentrations of neopterin, kynurenine and tryptophan in wound secretions of patients with breast cancer and malignant melanoma: a pilot study (2017) (1)
- [Neopterin and its importance in clinical diagnosis]. (1994) (1)
- Clinical and Biological Effects of Intraperitoneal Injections of Recombinant Interferon-g and Recombinant Interleukin 2 with or without Tumor-infiltrating Lymphocytes in Patients with Ovarian or Peritoneal Carcinoma 1 (2000) (1)
- [New trends in diagnostics and classification of breast carcinoma]. (2009) (1)
- Intestinal permeability-a prognostic indicator in ovarian cancer? (2008) (1)
- 925TiPA phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy (2017) (1)
- Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid (2012) (1)
- Phenotype of Peripheral Blood Leukocytes and Survival of Patients with Metastatic Colorectal Cancer (2005) (1)
- Complications and mortality of surgical therapy for esophageal cancer: 10 years single center experience. (2018) (1)
- 39th International Winter-Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics Innsbruck, February 25th - 28th, 2020 (2020) (1)
- Role of CCND1 and C-MYC oncogenes in metastatic breast cancer patients treated by herceptin (2011) (1)
- 37th International Winter-Workshop Clinical, Chemical and Biochemical Aspects of Pteridines and Related Topics (2018) (1)
- Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial. (2021) (1)
- Abstract P6-06-40: Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC) (2013) (0)
- P108 INTESTINAL PERMEABILITY DURING GEFITINIB TREATMENT (2008) (0)
- P-066S-1 in combination with epirubicin and oxaliplatin (EOS) in Caucasian patients (pts) with advanced or metastatic gastric cancer (AGC): Results of a phase I study (2015) (0)
- Correction to: Changes in expression of lysosomal membrane proteins in leucocytes of cancer patients treated with tyrosine kinase inhibitors (2021) (0)
- Correlation of an Aurora A single nucleotide polymorphism (SNP) with clinical responses to alisertib in patients (pts) with advanced solid tumors. (2016) (0)
- 1995 Pezcoller Award for Oncology: 100,000 E.C.U. (1994) (0)
- P9 Relations among expression of Ki-67, p53, hormonalreceptors and traditional clinicopathological features in stage I and II breast cancer (2005) (0)
- Medical Oncology, The Medical Oncology Centre of Rosebank, Johannesburg, (2014) (0)
- Peritoneal Carcinomatosis from Ovarian Cancer - Current Clinical Impact of Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy. (2019) (0)
- 0160: Immunohistochemically Detectable Prognostic Factors in Ovarian Cancer (2006) (0)
- Colorectal cancer and screening programs: not only analytical issues (2014) (0)
- Significance of systemic chemotherapy and hyperthermic intraperitoneal chemotherapy in primary and secondary peritoneal surface malignancies (2017) (0)
- Jillian Russyll (AKA Jill) Tate (2018) (0)
- Characterization of antigen recognition in tumor infiltrating lymphocytes in breast cancer (1996) (0)
- EP679 Case report: locally advanced rectal cancer in pregnancy (2019) (0)
- ACTA MEDICA 03 2019.indd (2019) (0)
- Bacillus Calmette-Guérin pneumonitis after intravesical instillation: Report of two cases and a review of the literature. (2023) (0)
- Monophasic synovial sarcoma of the lower extremity at 20 weeks of pregnancy: a case report and review of the literature (2019) (0)
- Circulating Vascular Endothelial Growth Factor, C-reactive Protein and Urinary Neopterin Concentrations During dose-dense Chemotherapy (2008) (0)
- Abstract LB-438: Circulating tumor cells in pancreatic carcinoma: negative prognostic factor (2012) (0)
- 211 Intraluminal high dose rate brachytherapy in the treatment of carcinomas of the subhepatic region (2003) (0)
- Pancreatic metastases from renal cell carcinoma: Prognostic relevance and outcome in patients treated with targeted agents. (2015) (0)
- The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer. (2022) (0)
- Robust and high-throughput lipidomic quantitation of human blood samples using flow injection analysis with tandem mass spectrometry for clinical use (2023) (0)
- O-0008ABITUZUMAB COMBINED WITH CETUXIMAB PLUS IRINOTECAN VERSUS CETUXIMAB PLUS IRINOTECAN ALONE, AS SECOND-LINE TREATMENT FOR PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: THE POSEIDON PHASE I/RANDOMIZED PHASE II TRIAL (2014) (0)
- Phenotype of peripheral blood leukocytes and survival of patients with metastatic colorectal cancer. (2005) (0)
- Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers) (2017) (0)
- Complications of the surgical treatment of esophageal cancer and microbiological analysis of the respiratory tract. (2019) (0)
- [Pancreatic cancer surgery at Ist Surgical Clinic of the Olomouc Faculty Hospital (FN Olomouc)]. (2010) (0)
- Growth Inhibitory Effects of Aromatic Fatty Acids on Ovarian Tumor Cell Lines 1 (2005) (0)
- [Chemotherapy of primary and secondary liver tumors]. (2002) (0)
- EP064/#192 Potential mechanism for ocular adverse events observed with tisotumab vedotin (2022) (0)
- Circulating concentrations of citrulline, neopterin, kynurenine, and tryptophan during chemoradiation in patients with cervical carcinoma (2021) (0)
- Contents Vol. 51, 2005 (2005) (0)
- EP1.04-21 Chronic Inflammation as Potential Predictive Factor of Nivolumab Therapy in Non-Small Cell Lung Cancer (2019) (0)
- Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. (2013) (0)
- Palbociclib (PAL) + cetuximab (CET) vs CET in patients (pts) with head and neck cancer: Asian subgroup analysis (2019) (0)
- Occult tumor cells in peritoneal lavage in pancreatic carcinoma patients. (2012) (0)
- Models of Distribution of Electric Field of Primary Cilia as Monopole Antennas (2018) (0)
- Metachronous pulmonary metastasis after resection of pancreatic ductal adenocarcinoma. Different clinical scenarios. Retrospective study. Supported by Ministry of Health CR (16-28375A) (2017) (0)
- P-153Regorafenib in the real-life clinical practice: data from the czech registry (2016) (0)
- F06Outcome of patients with pancreatic metastases from renal cell carcinoma: when the site matters (2015) (0)
- Expression of bcl-2 in breast cancer: correlation with clinicopathological characteristics and survival. (2008) (0)
- PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY (2020) (0)
- CMAR_A_255332 5365..5372 (2020) (0)
- The brave new world of oncology research. (2013) (0)
- PD PHASE III TRIAL EVALUATING THE ADDITION OF BEVACIZUMAB TO ENDOCRINE THERAPY AS FIRST-LINE TREATMENT FOR ADVANCED BREAST CANCER : THE GEICAM / GBG LEA STUDY (2012) (0)
- 6613 POSTER Genetic Polymorphism of Biotransforming Enzymes and Risk of Pancreatic Cancer (2011) (0)
- 4223 POSTER Urinary Neopterin Concentrations at Screening Predict Serious Adverse Events in Cancer Patients Enrolled in Clinical Trials (2011) (0)
- Association between negative preoperative axillary node staging and surgical sentinel node biopsy in patients with newly diagnosed breast cancer: A retrospective analysis. (2020) (0)
- Germline DNA-repair genetic background in long-term survivors of pancreatic ductal adenocarcinoma (2019) (0)
- Hepatic arterial infusion (HAI) in gastric cancer (GC) liver metastases (mets): A pooled analysis of the reported results (2004) (0)
- Evaluation and management of toxicity of cytoreductive surgery/hyperthermic intraperitoneal chemotherapy: the initial experience of a single centre study. (2019) (0)
- The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type. (2018) (0)
- Biomarkers of Inflammation and Progression During Immunotherapy in Patients With Metastatic Renal Cell Carcinoma (2023) (0)
- The importance of cytogenetic changes of Her-2/neu, C-MYC, RARA and CCND1 oncogenes in breast cancer patients (2010) (0)
- Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer (2016) (0)
- Hepatic arterial infusion (HAI) in gastric cancer (GC) liver metastases (mets): A pooled analysis of the reported results. (2004) (0)
- 258 Prognostic factors of survival after oxaliplatin therapy in colorectal cancer patients pretreated by irinotecan (2003) (0)
- of Metastatic Renal Cell Carcinoma: Final Safety and Efficacy Data From the Prospective BEVLiN Study 809P (2012) (0)
- Scene Pharmacogenomics : from cell to clinic ( Part 1 ) (2014) (0)
- TOP2A gene status in ‘triple negative’ breast cancer patients as a possible anthracycline response predictor (2010) (0)
- Prognosis and outcome of patients with pancreatic metastases from renal cell carcinoma: When the site matters. (2015) (0)
- EDITORIAL. The brave new world of oncology research (2013) (0)
- Prolonged response to pemetrexed-based chemotherapy in a patient with peritoneal mesothelioma: a case report and review of the literature (2016) (0)
- Mario Plebani turns 70 (2020) (0)
- [Evaluation of Anti-cancer Therapies with Reimbursement Limited to Comprehensive Cancer Centres Using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale]. (2017) (0)
- Phase II study on the efficacy and safety of lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu: Positive advanced breast cancer (CECOG LaVie Trial). (2015) (0)
- P-0211 The Prognostic Significance of Tumor Egfr Expression After Neoadjuvant Chemoradiation in Patients With Rectal Adenocarcinoma (2012) (0)
- Subject Index Vol. 51, 2005 (2005) (0)
- Serum Neopterin in Patients with Malignant Melanoma (2009) (0)
- Salivary and serum neopterin and interleukin 6 as biomarkers in patients with oral and oropharyngeal squamous cell carcinoma (2022) (0)
- Pancreatic cancer harboring germline BRCA 2 mutation, a case report of third line platinum-based chemotherapy. (2017) (0)
- Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial (2016) (0)
- Abstract P5-21-31: Treatment patterns and outcomes of pertuzumab in combination with trastuzumab and docetaxel as first-line treatment of metastatic HER-2 positive breast cancer : Comparison of Czech clinical registry and CLEOPATRA trial data (2018) (0)
- Management of Internal Mammary Nodes in Early-Stage Breast Cancer: Response to Comments by De Cicco et al (2016) (0)
- Testicular Choriocarcinoma with Jejunal Metastasis Complicated by Intestinal Perforation and Acute Peritonitis (2006) (0)
- [Gynecologic neoplasms in diabetic patients]. (2002) (0)
- [Activation of the immune system in colorectal carcinoma and its assessment]. (1997) (0)
- Hepatic arterial administration of autologous activated lymphocytes in patients with liver metastases (2001) (0)
- Mario Plebani and Bohuslav Melichar Quo vadis , biomarkers ? (2014) (0)
- Abstract P4-21-12: Preference of trastuzumab administration route (intravenous or subcutaneous) in patients in the Czech Republic. Cross-sectional study on 429 patients (2017) (0)
- Three lines of targeted therapy for metastatic renal cell carcinoma (mRCC): A viable strategy? (2013) (0)
- Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC) (2019) (0)
- Appendiceal tumors and pseudomyxoma peritonei: current recommendations for clinical practice. (2023) (0)
- Briefe an die Herausgeber – Letters to the Editors (1994) (0)
- Comparative fluorimetric determination of urinary neopterin by flow injection analysis and HPLC (1999) (0)
- The surgical resectability following neoadjuvant therapy in pancreatic head cancer (2012) (0)
- 2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies (2015) (0)
- Practical instructions for testing and targeted therapy in adult patients with solid tumours with NTRK gene fusion in common clinical practice. (2020) (0)
- Changes of lipid metabolism and its mediator-related effects in patients with colorectal carcinoma-prospective impact in nutritional support (2019) (0)
- Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. (2020) (0)
- Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma. (2023) (0)
- 2239 Long-term results of preoperative chemoradiation in clinically resectable gastroesophageal cancer: A single institution experience (2015) (0)
- Hepatic arterial infusion in liver tumors of unknown, uncertain or unusual primary: single-center experience. (2019) (0)
- Hyperprogression on anti-PD-1 treatment. Is subsequent therapy feasible? A case report and review of the literature. (2022) (0)
- Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis (2014) (0)
- P-0283THE DETECTION OF CIRCULATING TUMOR CELLS IN COLORECTAL CANCER USING QPCR AND ITS EFFECT ON ANALGESIA (2013) (0)
- Comparison of efficacy and toxicity of bevacizumab in combination with chemotherapy in the first, second, and third or higher line of treatment for metastatic colorectal carcinoma (mCRC): Data from the Czech multi-institutional registry. (2013) (0)
- 2731 Impact of frailty on outcome of elderly patients treated with hormone therapy for advanced/recurrent endometrial cancer (EC) (2015) (0)
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. (2023) (0)
- Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. (2023) (0)
- Prognostic Significance of Serum and Urinary Neopterin Concentrations in Patients (2015) (0)
- Intestinal Permeability and Toxicity of Second-Line Therapeutic Agents in Ovarian Cancer (2008) (0)
- Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer? (2008) (0)
- [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma]. (2013) (0)
- Comprehensive characterization of complex glycosphingolipids in human pancreatic cancer tissues (2023) (0)
- Evaluation of HER2 gene status by qPCR in breast cancer samples with nonconclusive FISH. (2011) (0)
- Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry (2017) (0)
- C16Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents (2016) (0)
- Abstract P6-10-02: MLN8237 (alisertib), an investigational Aurora A Kinase inhibitor, in patients with breast cancer: Emerging phase 2 results (2012) (0)
- Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients. (2021) (0)
- response from a randomized phase II study in metastatic renal cell carcinoma (2015) (0)
- Serum concentrations of TFF3, S100-A11 and AIF-1 in association with systemic inflammatory response, disease stage and nodal involvement in endometrial cancer (2018) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Bohuslav Melichar?
Bohuslav Melichar is affiliated with the following schools:
